Macairan v. People
REITERATIONFacts
1. The Antecedents: The cases involve the purchase of 10,000 bottles of Paracetamol Suspension and 1,500 bottles of Ferrous Sulfate with Vitamin B Complex and Folic Acid by the Department of Health - National Capital Region (DOH-NCR) in May 1996. An anonymous letter alleged irregularities in these purchases, implicating several pharmaceutical companies, including Aegis Pharmaceuticals and Lumar Pharmaceutical Laboratory. The Office of the Ombudsman subsequently found probable cause to charge petitioners with violations of Section 3(e) of Republic Act No. 3019, the Anti-Graft and Corrupt Practices Act, for allegedly giving unwarranted benefits to suppliers through overpriced procurements without public bidding. 2. Procedural History: Following the Ombudsman's resolution, Informations were filed with the Sandiganbayan. Criminal Case No. 26492 charged petitioners Majarais, Camposano, Cabrera, Du, Agustin, Perez, and Ocampo with violation of Section 3(e) of R.A. No. 3019 in relation to the purchase of Paracetamol Suspension from Aegis. Criminal Case No. 26493 charged Majarais, Camposano, Cabrera, Agustin, Perez, and Macairan with the same offense concerning the purchase of Ferrous Sulfate with Vitamin B Complex and Folic Acid from Lumar. The cases were jointly tried. The Sandiganbayan, in its Decision dated April 29, 2014, found most of the petitioners guilty beyond reasonable doubt, sentencing them to imprisonment and perpetual disqualification from public office. Priscilla G. Camposano was acquitted in Criminal Case No. 26492. The Sandiganbayan denied the petitioners' motions for reconsideration in a Resolution dated October 24, 2014. 3. The Petition: The consolidated Petitions for Review on Certiorari under Rule 45 of the Rules of Court were filed before the Supreme Court. Petitioners argue that the Sandiganbayan erred in finding them guilty, asserting that the prosecution failed to prove all the elements of the crime, specifically the existence of conspiracy, evident bad faith, manifest partiality, undue injury to the government, and unwarranted benefits to private parties. They contend that the absence of public bidding does not automatically equate to a violation of R.A. No. 3019, that their actions were based on established DOH policies regarding previous bidding results, and that the alleged overpricing was not sufficiently proven with comparable evidence. Furthermore, they argue that mere signatures on official documents do not establish conspiracy.
Issue(s)
Whether the Sandiganbayan erred in finding petitioners guilty beyond reasonable doubt of violation of Section 3(e) of R.A. No. 3019. Whether conspiracy was sufficiently established among the petitioners. Whether the prosecution proved the elements of Section 3(e) of R.A. No. 3019, namely: (1) that the accused is a public officer discharging administrative, judicial, or official functions; (2) that he acted with manifest partiality, evident bad faith, or gross inexcusable negligence; and (3) that his action caused undue injury to any party, including the Government, or gave any private party unwarranted benefits, advantage, or preference. Whether the prosecution sufficiently established overpricing of the purchased medicines. Whether the prosecution proved that the petitioners acted with evident bad faith and manifest partiality. Whether the prosecution proved that the transactions caused undue injury to the government or gave unwarranted benefits to private parties.
Ruling
The Supreme Court reversed and set aside the Decision and Resolution of the Sandiganbayan, acquitting all petitioners. The Court found the evidence insufficient to establish guilt beyond reasonable doubt.
Ratio Decidendi
On the issue of the Sandiganbayan's error: The Court found that the second and third elements of Section 3(e) of R.A. No. 3019 – manifest partiality, evident bad faith, or gross inexcusable negligence, and causing undue injury or giving unwarranted benefits – were not established beyond reasonable doubt. The Court concluded that the prosecution failed to prove the petitioners guilty beyond reasonable doubt. On the issue of conspiracy: The Court held that the prosecution failed to establish conspiracy among the petitioners. The Court emphasized that conspiracy requires proof beyond reasonable doubt of overt acts showing a common purpose or design. Mere signatures on official documents, such as Requisition and Issue Vouchers (RIVs), Purchase Orders (POs), and Disbursement Vouchers (DVs), are insufficient to establish conspiracy, as these may merely signify assent to standard operating procedures or certification of facts within one's official capacity. The Court cited previous rulings in Arias v. Sandiganbayan, Magsuci v. Sandiganbayan, and Sabiniano v. Court of Appeals to support the principle that conspiracy cannot be predicated solely on the performance of official duties or mere signatures without clear evidence of conscious and intentional participation in the planning, preparation, and execution of the crime. On the elements of Section 3(e) of R.A. No. 3019: The Court clarified that a violation of procurement law does not automatically equate to a violation of Section 3(e) of R.A. No. 3019. The prosecution must prove that the accused acted with malicious motive or fraudulent intent. The Court noted that the petitioners' resort to direct purchase was based on an honest belief that it was warranted under the circumstances, citing the DOH-NCR's policy of adopting results from previous winning bidders. The Court reiterated that mistakes or negligence are not actionable under R.A. No. 3019 without clear proof of malice or corrupt motive. On the issue of overpricing: The Court found the prosecution's evidence insufficient to establish overpricing. The DOH-Central Price List was a photocopy and did not clearly show that the prices pertained to the same brand, features, and specifications as the purchased medicines, especially given the admitted difference between paracetamol syrup and suspension. The Court also noted that the 1994 Abstract of Bids used to prove overpricing for Ferrous Sulfate was unreliable because it involved a disqualified bidder (Foramen) and did not establish that Lumar's bid was indeed overpriced compared to qualified bidders. The Court emphasized that proof of overpricing requires a comparison with identical items and a canvass of prices from different suppliers. On evident bad faith and manifest partiality: The Court found that the DOH-Central Price List, used by the Sandiganbayan to establish overpricing, was prepared after the questioned purchase, and there was no proof it was received by the DOH-NCR, thus negating knowledge and bad faith. On undue injury and unwarranted benefits: The Court concluded that the third element was not proven because the prosecution failed to establish evident bad faith and manifest partiality, and failed to prove with moral certainty that the questioned transactions were overpriced. The Court reiterated that the granting of unwarranted benefits or causing undue injury must be linked to a corrupt or fraudulent motive, which was absent in this case. The Court also noted the lack of proof that the petitioners personally profited from the transactions, emphasizing that R.A. No. 3019 targets corruption and dishonest gain.
Main Doctrine
The prosecution failed to establish conspiracy among the petitioners and failed to prove the elements of evident bad faith, manifest partiality, undue injury, or unwarranted benefits beyond reasonable doubt. Mere signatures on official documents do not automatically establish conspiracy. Violations of procurement law do not automatically equate to violations of Section 3(e) of R.A. No. 3019; the elements of the latter must still be proven, including corrupt motive or fraudulent intent. The prosecution also failed to sufficiently establish overpricing by comparing identical items and failed to prove undue injury or unwarranted benefits without proof of corrupt intent.